[go: up one dir, main page]

PE20251277A1 - OLIGONUCLEOTIDE - Google Patents

OLIGONUCLEOTIDE

Info

Publication number
PE20251277A1
PE20251277A1 PE2024002344A PE2024002344A PE20251277A1 PE 20251277 A1 PE20251277 A1 PE 20251277A1 PE 2024002344 A PE2024002344 A PE 2024002344A PE 2024002344 A PE2024002344 A PE 2024002344A PE 20251277 A1 PE20251277 A1 PE 20251277A1
Authority
PE
Peru
Prior art keywords
nitrogenous base
seq
nos
oligonucleotides
replaced
Prior art date
Application number
PE2024002344A
Other languages
Spanish (es)
Inventor
Zonneveld Anton Jan Van
Jurrien Prins
Der Veer Eric Peter Van
Bianca Matthee
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of PE20251277A1 publication Critical patent/PE20251277A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se refiere al campo de los oligonucleotidos que se unen a ARN de poliomavirus. Tales oligonucleotidos se pueden utilizar para el tratamiento de cualquier enfermedad o afeccion provocada por tales virus o asociada a ellos. El oligonucleotido comprende una secuencia de bases nitrogenadas de acuerdo con una de las SEQ ID NOs: 8, 1, 2, 3, 4, 5, 6, 7, 9, 10 y 11 o que comprende una secuencia de bases nitrogenadas que es analoga a una cualquiera de las SEQ ID NOs: 1 a 11 que se caracteriza por que al menos una base nitrogenada de dichas SEQ ID NOs se reemplaza por un analogo de base nitrogenada que tiene la misma especificidad de apareamiento de bases que la base nitrogenada reemplazada.It refers to the field of oligonucleotides that bind to polyomavirus RNA. Such oligonucleotides can be used for the treatment of any disease or condition caused by or associated with such viruses. The oligonucleotide comprises a nitrogenous base sequence according to one of SEQ ID NOs: 8, 1, 2, 3, 4, 5, 6, 7, 9, 10 and 11 or comprising a nitrogenous base sequence that is analogous to any one of SEQ ID NOs: 1 to 11 characterized in that at least one nitrogenous base of said SEQ ID NOs is replaced by a nitrogenous base analogue having the same base pairing specificity as the replaced nitrogenous base.

PE2024002344A 2022-05-06 2023-05-05 OLIGONUCLEOTIDE PE20251277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22172149 2022-05-06
PCT/IB2023/054702 WO2023214373A2 (en) 2022-05-06 2023-05-05 Oligonucleotide

Publications (1)

Publication Number Publication Date
PE20251277A1 true PE20251277A1 (en) 2025-05-14

Family

ID=81585836

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024002344A PE20251277A1 (en) 2022-05-06 2023-05-05 OLIGONUCLEOTIDE

Country Status (16)

Country Link
EP (1) EP4519437A2 (en)
JP (1) JP2025515168A (en)
KR (1) KR20250017212A (en)
CN (1) CN119384501A (en)
AR (1) AR129237A1 (en)
AU (1) AU2023265171A1 (en)
CA (1) CA3252028A1 (en)
CL (1) CL2024003337A1 (en)
CO (1) CO2024016360A2 (en)
CU (1) CU20240036A7 (en)
IL (1) IL316802A (en)
MX (1) MX2024013528A (en)
PE (1) PE20251277A1 (en)
TW (1) TW202400187A (en)
UY (1) UY40258A (en)
WO (1) WO2023214373A2 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683173B2 (en) 1998-04-03 2004-01-27 Epoch Biosciences, Inc. Tm leveling methods
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
WO2012143427A1 (en) * 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CN103998458B (en) 2011-08-30 2018-10-09 医学研究理事会 Cell-penetrating peptides with central hydrophibic domain
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
RU2708237C2 (en) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Modified oligonucleotides and method for production thereof
US10179817B2 (en) 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
AU2016264471B2 (en) 2015-05-19 2022-01-27 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR20180056766A (en) 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 Nucleotide compositions and methods thereof
CA3092817A1 (en) * 2018-03-02 2019-09-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Inhibition of polyomavirus replication

Also Published As

Publication number Publication date
AU2023265171A1 (en) 2024-11-07
CL2024003337A1 (en) 2025-07-18
AR129237A1 (en) 2024-07-31
CA3252028A1 (en) 2023-11-09
CN119384501A (en) 2025-01-28
CO2024016360A2 (en) 2025-02-24
KR20250017212A (en) 2025-02-04
TW202400187A (en) 2024-01-01
CU20240036A7 (en) 2025-07-09
WO2023214373A2 (en) 2023-11-09
UY40258A (en) 2023-11-15
IL316802A (en) 2025-01-01
WO2023214373A3 (en) 2024-01-11
JP2025515168A (en) 2025-05-13
MX2024013528A (en) 2024-12-06
EP4519437A2 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
AR113214A1 (en) PCSK9 EXPRESSION MODULATORS
AR115041A1 (en) ENGINEERED ENGINEERED OPTIMIZED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
AR127850A1 (en) 5-UTR WITH GREATER TRANSLATION EFFICIENCY, SYNTHETIC NUCLEIC ACID MOLECULE THAT INCLUDES IT AND VACCINE OR THERAPEUTIC COMPOSITION THAT INCLUDES IT
AR107579A1 (en) COMPOSITIONS AND METHODS TO DECREASE TAU EXPRESSION
AR126207A1 (en) ANTI-FLT1 OLIGONUCLEOTIDE COMPOUNDS OPTIMIZED FOR THE TREATMENT OF PRE-ECLAMPIA AND OTHER ANGIOGENIC DISORDERS
MX2023008469A (en) Modified double stranded oligonucleotides.
AR084319A1 (en) MicroRNA INHIBITORS (miRNA OR miR) THAT INCLUDE BLOCKED NUCLEOTIDES
AR115416A1 (en) MODULATORS OF APOL1 EXPRESSION
PE20211238A1 (en) ANTI-SENSE TREATMENT OF ANGELMAN SYNDROME
CU20170001A7 (en) PHARMACEUTICAL COMPOSITIONS OF NUCLEIC ACID POLYMER PHOSPHOROTIOATE AND NUCLEOSIDE / NUCLEOTIDE ANALOG, USEFUL FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D
CO2022014031A2 (en) Compounds for use in viral infections
MX2022015365A (en) Compositions and methods for treating long covid.
MX2021012051A (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof.
CO2019010062A2 (en) Novel clostridium perfringens bacteriophage clo-pep-2 and its use to inhibit the proliferation of clostridium perfringens
BR112022012350A2 (en) HIGH-FIDELITY SPCAS9 NUCLEASES FOR GENOME MODIFICATION
MX2025002405A (en) Pharmaceutical compositions for herpes virus
PE20212248A1 (en) OLIGOMERIC MOLECULE OF NUCLEIC ACID AND USE OF IT
AR126070A1 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4)
PE20251277A1 (en) OLIGONUCLEOTIDE
AR083445A1 (en) siRNA AGAINST FIBROSIS
CO2020010533A2 (en) Novel salmonella heidelberg sal-hep-1 bacteriophage and its use to inhibit the growth of salmonella heidelberg bacteria
AR107504A1 (en) NUCLEOTIDE SEQUENCE AND METHOD FOR CONTROLLING INVASIONS OF INSECTS
CL2025000116A1 (en) Compositions and pharmaceutical forms for the treatment of HPV infection and HPV-induced neoplasia
MX2022012618A (en) APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTIONS.
AR061168A1 (en) INHIBITION THROUGH ARNI OF WHITES RELATED TO FACTOR 1 DERIVED FROM STORM CELLS FOR THE TREATMENT OF DISEASES RELATED TO NEOVASCULARIZATION